OXECTA^®

Acura’s lead product, OXECTA^® (oxycodone HCI, USP) Tablets CII, or OXECTA^®, was approved for marketing by the United States Food and Drug Administration (FDA) on June 17, 2011. OXECTA^® represents the first immediate-release oxycodone product approved by the FDA that applies Acura’s AVERSION^® Technology. AVERSION^® is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering.

OXECTA^® is being manufactured and commercialized by Pfizer under our October 2007 license agreement with a subsidiary of Pfizer and was made commercially available by Pfizer beginning in January 2012.

Other AVERSION^® Products in Development

Acura has developed several other tamper-resistant opioid products using AVERSION^® Technology. The Company is currently considering commercialization opportunities for these products and product candidates.

NEXAFED^®

Acura has developed NEXAFED^®, an over-the-counter, or OTC, immediate-release pseudoephedrine HCl (PSE) tablet, utilizing the Company’s proprietary IMPEDE^® Technology. PSE is a widely-used nasal decongestant available in many non-prescription and prescription cold, sinus and allergy products, including Johnson & Johnson’s Sudafed^® product. Acura’s IMPEDE^® Technology is a proprietary mixture of inactive ingredients designed to disrupt the extraction or direct conversion of PSE in tablets into methamphetamine.

Acura intends to introduce NEXAFED^® into pharmacies either directly or through a distribution partnership.